News

Vascular experts establish Appropriate Use of Intravascular Ultrasound (IVUS) in peripheral interventions

Philips intravascular ultrasound (IVUS) - 1 Philips intravascular ultrasound (IVUS) - 2 August 12, 2022 First-ever global consensus guidance published…

2 years ago

Nova Leap Health Corp. Posts Q2 2022 Results

Revenue in USD Revenue In USD Adjusted EBITDA & Operating Income (Loss) in USD $ Adjusted EBITDA & Operating Income…

2 years ago

IR-Med files Provisional Patent Application Covering Additional Features of its PressureSafe Device for Early Detection of Pressure Injuries

Rosh Pinna, Israel, Aug. 12, 2022 (GLOBE NEWSWIRE) -- (“IR-MED or the “Company”) (OTCQB:IRME), an innovative medical device company, developing…

2 years ago

Biofrontera Inc. Reports Second Quarter 2022 Financial Results and Provides a Business Update

Conference call begins at 11:00 a.m. Eastern time today WOBURN, Mass., Aug. 12, 2022 (GLOBE NEWSWIRE) -- Biofrontera Inc. (Nasdaq:…

2 years ago

Relief Therapeutics and Acer Therapeutics Announce that the European Commission Has Granted Orphan Drug Designation for ACER-001 in Maple Syrup Urine Disease

Orphan designation provides potential for up to 10-year market exclusivity in the EU upon regulatory approvalGENEVA, Switzerland and NEWTON, Mass.,…

2 years ago

Milestone Scientific Schedules Second Quarter 2022 Financial Results and Business Update Conference Call

ROSELAND, N.J., Aug. 12, 2022 (GLOBE NEWSWIRE) -- Milestone Scientific Inc. (NYSE:MLSS), a leading developer of computerized drug delivery instruments,…

2 years ago

POINT Biopharma Reports Second Quarter 2022 Financial Results and Provides Business Highlights

Additional data from the lead-in of PNT2002's SPLASH trial on track for fall 2022 release PNT6555, the lead of the…

2 years ago

Palisade Bio Announces Pricing of $12 Million Upsized Underwritten Public Offering

CARLSBAD, Calif., Aug. 12, 2022 (GLOBE NEWSWIRE) -- Palisade Bio (Nasdaq: PALI), a clinical stage biopharmaceutical company advancing therapies for…

2 years ago

Checkpoint Therapeutics Reports Second Quarter 2022 Financial Results and Recent Corporate Highlights

Positive interim results from registration-enabling study of cosibelimab in locally advanced cutaneous squamous cell carcinoma announced in June 2022 Successful…

2 years ago

VYNE Therapeutics Reports Second Quarter 2022 Financial Results

BRIDGEWATER, N.J., Aug. 12, 2022 (GLOBE NEWSWIRE) -- VYNE Therapeutics Inc. (Nasdaq: VYNE) (“VYNE” or the “Company”), a biopharmaceutical company…

2 years ago